 The purpose of this study is to show that vaccination with a single dose of GSK Biologicals pandemic H1N1 vaccine results in an immune response that meets or exceeds European Medicines Agency EMEA Committee for Medicinal Products for Human Use CHMP guidance criteria for a pandemic influenza vaccine. 